StreetInsider.com News Articles

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Fri, 29 May 2026 07:00:00 -0400

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members

Research will also assess the clinical impact of broader genetic testing in colorectal cancer care

Labcorp (LH) Launches Expanded DPYD Test

Thu, 28 May 2026 07:03:32 -0400

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).

"Advances in pharmacogenomics are reshaping cancer care," said Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "Our expanded

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Thu, 28 May 2026 07:00:00 -0400

New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment

BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Thu, 28 May 2026 07:00:00 -0400

New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Thu, 28 May 2026 07:00:00 -0400

New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Thu, 28 May 2026 07:00:00 -0400

New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment